| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BETHESDA, Md.—Looking to strengthen and expand its national network of vaccine and treatment evaluation units (VTEUs), the National Institute of Allergy and Infectious Diseases (NIAID) announced the awarding of eight new contracts to institutions across the country. Each VTEU will receive approximately $23.7 million over seven years to increase the number of clinical trials, using larger volunteer populations of wider scope, including the typically underevaluated infants and elderly.
 
"In more than four decades of research, the VTEUs have conducted hundreds of clinical trials of investigational vaccines and therapeutics for a variety of infectious diseases of public health concern, and many of these trials have contributed to the licensure of products," says NIAID Director Dr. Anthony Fauci. "We expect this success to continue, as each VTEU has exceptional expertise and experience in vaccinology and an impressive capacity to recruit volunteers from diverse populations in its community."
 
The move comes at a critical time for the pharmaceutical and biotech industries as more companies are exploring the world of vaccines with mixed success. For example, at the same time that Merck is riding high on the widespread success and rapid uptake of its HPV vaccine Gardasil, it is also monitoring public concerns over the safety of its experimental AIDS vaccine, which the company pulled from trial in September.
 
Despite the concerns, the market is growing rapidly. According to a recent report by Kalorama Information, the global market for vaccines is expected to surpass the $10-billion mark in 2007 and may reach $15 billion by 2012, with cancer vaccines taking the lion's share.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue